Header Logo

Connection

Rosemarie Martin to Opioid-Related Disorders

This is a "connection" page, showing publications Rosemarie Martin has written about Opioid-Related Disorders.
Connection Strength

3.684
  1. Kang AW, Bailey A, Surace A, Stein L, Rohsenow D, Martin RA. Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders. Addict Sci Clin Pract. 2024 Dec 18; 19(1):95.
    View in: PubMed
    Score: 0.549
  2. Bailey A, DaCunha A, Napoleon SC, Kang AW, Kemo M, Martin RA. Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review. J Subst Use Addict Treat. 2024 Sep; 164:209431.
    View in: PubMed
    Score: 0.529
  3. Martin RA, Berk J, Rich JD, Kang A, Fritsche J, Clarke JG. Use of long-acting injectable buprenorphine in the correctional setting. J Subst Abuse Treat. 2022 11; 142:108851.
    View in: PubMed
    Score: 0.465
  4. Stahler GJ, Mennis J, Stein LAR, Belenko S, Rohsenow DJ, Grunwald HE, Brinkley-Rubinstein L, Martin RA. Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015-2018. Drug Alcohol Depend. 2022 07 01; 236:109498.
    View in: PubMed
    Score: 0.459
  5. Martin RA, Stein LAR, Rohsenow DJ, Belenko S, Hurley LE, Clarke JG, Brinkley-Rubinstein L. Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol. J Subst Abuse Treat. 2021 09; 128:108364.
    View in: PubMed
    Score: 0.423
  6. Martin RA, Gresko SA, Brinkley-Rubinstein L, Stein LAR, Clarke JG. Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Prev Med. 2019 11; 128:105766.
    View in: PubMed
    Score: 0.376
  7. Martin RA, Rohsenow DJ, Tidey JW. Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. J Subst Abuse Treat. 2019 09; 104:22-27.
    View in: PubMed
    Score: 0.374
  8. Kaplowitz E, Truong AQ, Berk J, Martin RA, Clarke JG, Wieck M, Rich J, Brinkley-Rubinstein L. Treatment preference for opioid use disorder among people who are incarcerated. J Subst Abuse Treat. 2022 06; 137:108690.
    View in: PubMed
    Score: 0.111
  9. Howell BA, Martin RA, Lebeau R, Truong AQ, Wang EA, Rich JD, Clarke JG. Changes In Health Services Use After Receipt Of Medications For Opioid Use Disorder In A Statewide Correctional System. Health Aff (Millwood). 2021 08; 40(8):1304-1311.
    View in: PubMed
    Score: 0.109
  10. Macmadu A, Adams JW, Bessey SE, Brinkley-Rubinstein L, Martin RA, Clarke JG, Green TC, Rich JD, Marshall BDL. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study. Int J Drug Policy. 2021 05; 91:102841.
    View in: PubMed
    Score: 0.101
  11. Macmadu A, Goedel WC, Adams JW, Brinkley-Rubinstein L, Green TC, Clarke JG, Martin RA, Rich JD, Marshall BDL. Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails. Drug Alcohol Depend. 2020 03 01; 208:107858.
    View in: PubMed
    Score: 0.098
  12. Clarke JG, Martin RA, Gresko SA, Rich JD. The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System. Am J Public Health. 2018 10; 108(10):1323-1325.
    View in: PubMed
    Score: 0.089
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.